地特胰岛素联合伏格列波糖治疗2型糖尿病临床疗效观察

Clinical observation of detemir combined with voglibose in the treatment of type 2 diabetes

目的探讨地特胰岛素联合伏格列波糖治疗2型糖尿病患者的临床疗效.方法将92例2型糖尿病患者按照随机数字表法分为两组,每组46例.观察组给予地特胰岛素联合伏格列波糖治疗,对照组给予门冬胰岛素30治疗,比较两组治疗前后空腹血糖、餐后2 h血糖、体质量指数、血清肿瘤坏死因子-α、C反应蛋白、白细胞介素-6水平变化情况,比较两组不良反应发生率.结果治疗后两组空腹血糖、餐后2 h血糖水平及体质量指数均较治疗前显著下降(P<0.05或0.01),观察组较对照组下降更显著(P<0.01).治疗后两组肿瘤坏死因子-α、C反应蛋白、白细胞介素-6水平均显著低于治疗前(P<0.01),观察组较对照组下降更显著(P<0.01).两组患者不良反应发生率比较差异无统计学意义(P>0.05).结论地特胰岛素联合伏格列波糖可有效控制2型糖尿病患者的血糖水平,降低体质量,改善炎症状态,安全性高.

Objective To investigate the clinical efficacy of detemir combined with voglibose in the treatment of type 2 diabetes.Methods 92 patients with T2DM were divided into two groups according to random number table,46 cases each.The observation group was given detemir plus voglibose,and the con-trol group was given insulin aspart 30.The levels of blood sugar,2h postprandial blood sugar,body mass index,TNF-alpha,CRP and IL-6 before and after treatment in both g roups were compared.The incidence of adverse reactions was compared between the two groups.Results After treatment,the fasting blood glucose,2 h postprandial blood glucose level and body mass index of the two groups were significantly lower than those before treatment(P<0.05 or 0.01),and the observation group decreased more significantly than the control g roup(P<0.01).After treatment,the levels of TN F-alpha,Creactive protein and interleukin-6 were significantly lower than those before treatment(P<0.01).The observation group decreased more significantly than the control group(P<0.01).There was no significant difference in the incidence of adverse reactions between the tw o groups(P>0.05).Conclusions Detemir in combination with voglibose can effectively control blood glucose levels in T2DM patients,reduce body mass,improve inflammatory status,and have high safety.